🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

24 results for “Genmab” Clear

  1. BENDAMUSTINE , TOCILIZUMAB , SILTUXIMAB , GEMCITABINE , ANAKINRA , Epcoritamab, DIPHENHYDRAMINE , PARACETAMOL , DEXAMETHASONE , RITUXIMAB , OXALIPLATIN , Epcoritamab

    Genmab A/S

    B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  2. DOXORUBICIN , Rinatabart Sesutecan, PACLITAXEL

    Genmab A/S

    Endometrial Cancer Advanced, Recurrent, Metastatic, or Primary Unresectable Endometrial Cancer

    phase 3 small molecule active

    1 trial

  3. METHYLPREDNISOLONE , CellCept 500 mg film-coated tablets, PREDNISONE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOCETAXEL , ANAKINRA , RoActemra 20 mg/mL concentrate for solution for infusion, DEXAMETHASONE , Acasunlimab

    Genmab A/S

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  4. PEGFILGRASTIM , PACLITAXEL , DOXORUBICIN , Rinatabart Sesutecan, GEMCITABINE , TOPOTECAN

    Genmab A/S

    Platinum-resistant Ovarian Cancer

    phase 3 small molecule active

    1 trial

  5. Abraxane 5 mg/ml powder for dispersion for infusion., PEMETREXED , GEN1042 DP, CARBOPLATIN , FLUOROURACIL , PACLITAXEL , PEMBROLIZUMAB, GEMCITABINE , CISPLATIN

    Genmab A/S

    Malignant solid tumors: Patients with relapsed or refractory, advanced and/or metastatic melanoma, Non-Small Cell Lung Cancer (NSCLC), Head and neck squamous cell carcinoma (HNSCC), Panctreatic ductal adenocarcinoma (PDAC) or Colorectal Cancer (CRC).

    phase 2 small molecule active

    1 trial

  6. Acasunlimab, Abraxane 5 mg/ml powder for dispersion for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pemetrexed Accord 100 mg powder for concentrate for solution for infusion., Cisplatin 1mg/ml Injection BP, Carboplatin 10 mg/ml Intravenous Infusion, Pazenir 5 mg/ml powder for dispersion for infusion., Abraxane 5 mg/ml powder for dispersion for infusion.

    Genmab A/S

    Malignant solid tumors: endometrial carcinoma (EC), urothelial carcinoma (UC), triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck (SCCHN), or cervical cancer.

    phase 2 small molecule active

    1 trial

  7. Acasunlimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Genmab A/S

    Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), Metastatic Cutaneous Melanoma (Stage IV)

    phase 2 small molecule active

    1 trial

  8. DIPHENHYDRAMINE , ANAKINRA , DEXAMETHASONE , Epcoritamab, SILTUXIMAB , PREDNISOLONE , TOCILIZUMAB , PARACETAMOL , Epcoritamab

    Genmab A/S

    Lymphoma of B-cell origin

    phase 2 small molecule active

    1 trial

  9. Epcoritamab, Epcoritamab, PARACETAMOL , ANAKINRA , LENALIDOMIDE , DEXAMETHASONE , DIPHENHYDRAMINE , SILTUXIMAB , TOCILIZUMAB

    Genmab A/S

    DIFFUSE LARGE B CELL LYMPHOMA

    phase 2 small molecule active

    1 trial

  10. GEN1042 DP, PEMBROLIZUMAB

    Genmab A/S

    Metastatic Solid Malignant tumors

    phase 2 small molecule active

    1 trial

  11. GEN1047 DP

    Genmab A/S

    Malignant Solid Tumors

    phase 2 small molecule active

    1 trial

  12. GEN1078 DP

    Genmab A/S

    Malignant solid tumors

    phase 2 small molecule active

    1 trial

  13. GEN3014 DP, DARZALEX 1800 mg solution for injection

    Genmab A/S

    Relapsed or Refractory Multiple Myeloma (RRMM) Diffuse Large B Cell Lymphoma (DLBCL) Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  14. HuMax-TF-ADC, CARBOPLATIN , PEMBROLIZUMAB , BEVACIZUMAB

    Genmab A/S

    Recurrent or stage IVB cervical cancer

    phase 2 small molecule active

    1 trial

  15. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Acasunlimab

    Genmab A/S

    Malignant Solid Tumors - Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  16. PEGFILGRASTIM , Rinatabart Sesutecan

    Genmab A/S

    Locally advanced or metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  17. PEMETREXED DISODIUM, PEMBROLIZUMAB, PEMBROLIZUMAB, PACLITAXEL, GEN1055 DP, CISPLATIN, GEMCITABINE, PACLITAXEL ALBUMIN-BOUND, CARBOPLATIN

    Genmab A/S

    Malignant Solid Tumors

    phase 2 small molecule active

    1 trial

  18. SILTUXIMAB , PREDNISOLONE , CYCLOPHOSPHAMIDE , CARBOPLATIN , PARACETAMOL , ETOPOSIDE , VINCRISTINE , LENALIDOMIDE , DIPHENHYDRAMINE , GEMCITABINE , PREDNISONE , OXALIPLATIN , TOCILIZUMAB , Epcoritamab, Epcoritamab, DEXAMETHASONE , DOXORUBICIN , CYTARABINE , RITUXIMAB , IFOSFAMIDE , ANAKINRA , BENDAMUSTINE

    Genmab A/S

    Lymphoma of B-cell origin

    phase 2 small molecule active

    1 trial

  19. VENETOCLAX , Epcoritamab, Epcoritamab, VINCRISTINE , Jaypirca 100 mg film-coated tablets, DOXORUBICIN , Jaypirca 50 mg film-coated tablets, CYCLOPHOSPHAMIDE , PREDNISOLONE , LENALIDOMIDE , RITUXIMAB

    Genmab A/S

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  20. A Study of GEN1106 in Participants with Solid Tumors

    Genmab A/S

    Metastatic or advanced malignant solid tumors

    phase 1 other active

    1 trial

  21. First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)

    Genmab A/S

    Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

    phase 1 other active

    1 trial

  22. Study of safety and antitumor activity of GEN1056 in participants with advanced solid tumors

    Genmab A/S

    Advanced solid tumors

    phase 1 other active

    1 trial

  23. Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants with Advanced Solid Tumors

    Genmab A/S

    Advanced Malignant Solid Tumors

    phase 1 other active

    1 trial

  24. Trial to assess the safety and antitumor activity of GEN1057 on malignant solid tumors

    Genmab A/S

    Metastatic or advanced malignant solid tumors

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources